How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3).

abstract：:Lung cancer is a leading cause of cancer deaths for both men and women across the world. In the past, studies on lung cancer have focused on traditional end points such as survival, disease-free survival or local control. More recently, investigators have begun to appreciate the importance of health-related quality-of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Siddiqui F,Konski AA,Movsas B

更新日期：2010-12-01 00:00:00

abstract：:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuipers P,Foster MM,Bellamy N

更新日期：2003-04-01 00:00:00

abstract：:It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feldman SR,Pearce DJ

更新日期：2004-10-01 00:00:00

abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

更新日期：2011-06-01 00:00:00

abstract：:Healthcare reform in any nation is an evolving process. Brought about by demographic, technological, social, cultural, economic and political factors, all healthcare systems are continually confronting issues related to cost, access and quality. This paper examines other countries' approaches to healthcare in the ongo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： O'Rourke TW,Iammarino NK

更新日期：2002-06-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：INTRODUCTION:Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. AREAS COVERED:We searched the literature for the co...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rehm J,Barbosa C

更新日期：2018-02-01 00:00:00

abstract：:The 10th consecutive World Health Economics conference was organized jointly by International Health Economics Association and European Conference on Health Economics Association and took place at The Trinity College, Dublin, Ireland in July 2014. It has attracted broad participation from the global professional commu...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Jakovljevic MB,Getzen TE,Torbica A,Anegawa T

更新日期：2014-12-01 00:00:00

abstract：:This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

更新日期：2007-02-01 00:00:00

abstract：:A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Shepherd J,Jones J

更新日期：2007-12-01 00:00:00

abstract：:The second symposium of the European Organisation for Research and Treatment of Cancer took place in September 2011 at the European Parliament in Brussels (Belgium). The aim of the symposium was to discuss a wide range of topics in health-related quality of life, symptom research and cancer clinical trials, including ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Dormer L

更新日期：2011-12-01 00:00:00

abstract：:Research on the quality of life (QL) of children/adolescents with psychological disorders has flourished over the last few decades. Given the developmental challenges of QL measurements in pediatric populations, the aim of this study was to ascertain the extent to which a developmental approach to QL assessment has be...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Carona C,Silva N,Moreira H

更新日期：2015-02-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：:Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

更新日期：2010-10-01 00:00:00

abstract：:The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Zhou XH,Ramsey S

更新日期：2003-10-01 00:00:00

abstract：:Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2003-06-01 00:00:00

abstract：OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feig C,Cheung KL,Hiligsmann M,Evers SMAA,Simon J,Mayer S

更新日期：2018-04-01 00:00:00

abstract：OBJECTIVE:This systematic review and meta-analysis aimed to reassess the effectiveness of condoms in reducing heterosexual transmission of HIV. METHODS:Medline, Scopus, and the ISI Web of Science databases were searched up to June 2014. Eligible studies were synthesized using random-effects models. RESULTS:Twenty-fiv...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Giannou FK,Tsiara CG,Nikolopoulos GK,Talias M,Benetou V,Kantzanou M,Bonovas S,Hatzakis A

更新日期：2016-08-01 00:00:00

abstract：:The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

更新日期：2010-02-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

更新日期：2020-08-01 00:00:00

abstract：OBJECTIVE:Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). METHODS:Little Australia-w...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Taylor PS,Faeth I,Marks MK,Del Mar CB,Skull SA,Pezzullo ML,Havyatt SM,Coates HL

更新日期：2009-04-01 00:00:00

abstract：:Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hirsch EB,Tam VH

更新日期：2010-08-01 00:00:00

abstract：OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cangelosi MJ,Ortendahl JD,Meckley LM,Bentley TG,Anene AM,Shriner KM,Fox J

更新日期：2015-04-01 00:00:00

abstract：:A review was undertaken to identify relevant and appropriate heath-utility estimates for patients with atrial fibrillation who had stroke and to appraise them against the published requirements for several countries' Health Technology Assessment agencies: Australia (Pharmaceutical Benefits Advisory Committee), Canada ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lloyd A,Wild D,Gallop K,Cowell W

更新日期：2009-12-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

更新日期：2012-06-01 00:00:00

abstract：:Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brédart A,Sultan S,Regnault A

更新日期：2010-04-01 00:00:00

abstract：:The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thicknes...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cormier JN,Xing Y,Ross MI,Cantor SB

更新日期：2004-12-01 00:00:00

abstract：BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

更新日期：2018-04-01 00:00:00

abstract：:In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Diaby V,Goeree R

更新日期：2014-02-01 00:00:00